Hyaluronic acid derivative-based self-assembled nanoparticles for the treatment of melanoma

Pharmaceutical Research

Volumn 29, Issue 12, 2012, Pages 3443-3454

  Jin, Yu Jin ^a   Termsarasab, Ubonvan ^a   Ko, Seung Hak ^b   Shim, Jae Seong ^b,c   Chong, Saeho ^a   Chung, Suk Jae ^a   Shim, Chang Koo ^a   Cho, Hyun Jong ^d   Kim, Dae Duk ^a  

^a Seoul National University   (South Korea)

^b Biogenics Inc   (South Korea)

^c Skin Tech Inc   (South Korea)

^d Sunchon National University   (South Korea)

Author keywords

Antitumor efficacy; Doxorubicin; Hyaluronic acid ceramide; Melanoma; Nanoparticle

Indexed keywords

CELL RECEPTOR; CERAMIDE; DOXORUBICIN; HYALURONIC ACID DERIVATIVE; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER MODEL; CELL STRAIN; CELL STRAIN B16F10; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG EFFICACY; DRUG RELEASE; DRUG TUMOR LEVEL; ENDOCYTOSIS; FEMALE; FLOW CYTOMETRY; IN VITRO STUDY; MELANOMA; MOUSE; NONHUMAN; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; WEIGHT CHANGE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CERAMIDES; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; HYALURONIC ACID; MELANOMA; MICE; MICE, INBRED C57BL; NANOPARTICLES;

EID: 84872056800     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0839-9     Document Type: Article

References (42)

1. Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res. 1976;36(8):2891-5.
2. Laginha KM, Verwoert S, Charrois GJR, Allen TM. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res. 2005;11(19):6944-9. (Pubitemid 41428752)
3. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710-7. (Pubitemid 10218041)
4. Kawashima Y, Yamamoto H, Takeuchi H, Kuno Y. Mucoadhesive DL-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm Dev Technol. 2000;5(1):77-85. (Pubitemid 30069202)
5. Choi KY, Chung H, Min KH, Yoon HY, Kim K, Park JH, et al. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials. 2010;31(1):106-14.
6. Li N, Wang J, Yang X, Li L. Novel nanogels as drug delivery systems for poorly soluble anticancer drugs. Colloids Surf B Biointerfaces. 2011;83(2):237-44.
7. Chen MC, Tsai HW, Liu CT, Peng SF, Lai WY, Chen SJ, et al. A nanoscale drug-entrapment strategy for hydrogel-based systems for the delivery of poorly soluble drugs. Biomaterials. 2009;30(11):2102-11.
8. Mahmud A, Xiong X, Lavasanifar A. Development of novel polymeric micellar drug conjugates and nano-containers with hydrolyzable core structure for doxorubicin delivery. Eur J Pharm Biopharm. 2008;69(3):923-34.
9. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines. J Drug Target. 2007;15(7-8):457-64. (Pubitemid 47209047)
10. Fukumori Y, Ichikawa H. Nanoparticles for cancer therapy and diagnosis. Adv Powder Technol. 2006;17(1):1-28. (Pubitemid 43259046)
11. Iinuma H, Maruyama K, Okinaga K, Sasaki K, Sekine T, Ishida O, et al. Intracellular targeting therapy of cisplatin-encapsulated transferrin- polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer. 2002;99(1):130-7. (Pubitemid 34273210)
12. Kobayashi T, Ishida T, Okada Y, Ise S, Harashima H, Kiwada H. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int J Pharm. 2007;329(1-2):94-102. (Pubitemid 44937528)
13. Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, Gunaseelan S, et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A. 2005;102(36):12962-7. (Pubitemid 41279472)
14. Laurent TC. The chemistry, biology and medical applications of hyaluronan and its derivatives. London: Portland; 1998.
15. Prestwich G, Marecak D, Marecek J, Vercruysse K, Ziebell M. Controlled chemical modification of hyaluronic acid: synthesis, applications, and biodegradation of hydrazide derivatives. J Control Release. 1998;53(1-3):93-103. (Pubitemid 28218693)
16. Price R, Berry M, Navsaria H. Hyaluronic acid: the scientific and clinical evidence. J Plastic Reconstr Aesthet Surg. 2007;60(10):1110-9. (Pubitemid 47342381)
17. Culty M, Shizari M, Thompson E, Underhill C. Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: correlation with invasive potential. J Cell Physiol. 1994;160(2):275-86. (Pubitemid 24259562)
18. Akima K, Ito H, Iwata Y, Matsuo K, Watari N, Yanagi M, et al. Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity. J Drug Target. 1996;4(1):1-8. (Pubitemid 26257699)
19. He M, Zhao Z, Yin L, Tang C, Yin C. Hyaluronic acid coated poly (butyl cyanoacrylate) nanoparticles as anticancer drug carriers. Int J Pharm. 2009;373(1-2):165-73.
20. Saddoughi SA, Song P, Ogretmen B. Roles of bioactive sphingolipids in cancer biology and therapeutics. In: Quinn PJ, Wang X, editors. Lipids in health and disease. Netherlands: Springer; 2008. p. 413-40.
21. Cho HJ, Yoon HY, Koo H, Ko SH, Shim JS, Lee JH, et al. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel. Biomaterials. 2011;32(29):7181-90.
22. Cho HJ, Yoon IS, Yoon HY, Koo H, Jin YJ, Ko SH, et al. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. Biomaterials. 2012;33(4):1190-200.
23. Choi KY, Yoon HY, Kim JH, Bae SM, Park RW, Kang YM, et al. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano. 2011;5(11):8591-9.
24. Chang JE, Shim WS, Yang SG, Kwak EY, Chong S, Kim DD, et al. Liver cancer targeting of doxorubicin with reduced distribution to the heart using hematoporphyrin-modified albumin nanoparticles in rats. Pharm Res. 2012;29(3):795-805.
25. Cai S, Thati S, Bagby TR, Diab HM, Davies NM, Cohen MS, et al. Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer. J Control Release. 2010;146(2):212-8.
26. Luo Y, Bernshaw NJ, Lu ZR, Kopecek J, Prestwich GD. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates. Pharm Res. 2002;19(4):396-402. (Pubitemid 34408935)
27. Kim DH, An EJ, Kim J, Han SH, Kim JW, Oh SG, et al. Fabrication and characterization of pseudo-ceramide-based liposomal membranes. Colloids Surf B Biointerfaces. 2009;73(2):207-11.
28. Liao YH, Jones SA, Forbes B, Martin GP, Brown MB. Hyaluronan: pharmaceutical characterization and drug delivery. Drug Deliv. 2005;12(6):327-42. (Pubitemid 41572107)
29. Ma Y, Tang Y, Billingham NC, Armes SP, Lewis AL, Lloyd AW, et al. Well-defined biocompatible block copolymers via atom transfer radical polymerization of 2-methacryloyloxyethyl phosphorylcholine in protic media. Macromolecules. 2003;36(10):3475-84.
30. Lavasanifar A, Samuel J, Kwon GS. Micelles self-assembled from poly (ethylene oxide)-block-poly (N-hexyl stearate-aspartamide) by a solvent evaporation method: effect on the solubilization and haemolytic activity of amphotericin B. J Control Release. 2001;77(1-2):155-60. (Pubitemid 33022624)
31. Yokoyama M. Drug targeting with nano-sized carrier systems. J Artif Organs. 2005;8(2):77-84. (Pubitemid 41139586)
32. Liu D, Mori A, Huang L. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta. 1992;1104(1):95-101.
33. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release. 2005;109(1-3):169-88. (Pubitemid 41742123)
34. Choi YK, Lee DW, Yong CS, Choi HG, Bronich TK, Kim JO. Biostable poly (ethylene oxide)-b-poly (methacrylic acid) micelles for pH-triggered release of doxorubicin. J Pharm Invest. 2011;41(2):111-5.
35. Nukolova NV, Oberoi HS, Cohen SM, Kabanov AV, Bronich TK. Folate-decorated nanogels for targeted therapy of ovarian cancer. Biomaterials. 2011;32(23):5417-26.
36. Prabaharan M, Grailer JJ, Pilla S, Steeber DA, Gong S. Folate-conjugated amphiphilic hyperbranched block copolymers based on Boltorn® H40, poly (l-lactide) and poly (ethylene glycol) for tumor-targeted drug delivery. Biomaterials. 2009;30(16):3009-19.
37. Liu H, Farrell S, Uhrich K. Drug release characteristics of unimolecular polymeric micelles. J Control Release. 2000;68(2):167-74. (Pubitemid 30488894)
38. Fritze A, Hens F, Kimpfler A, Schubert R, Peschka-Süss R. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta. 2006;1758(10):1633-40. (Pubitemid 44466698)
39. Eliaz RE, Nir S, Marty C, Szoka Jr FC. Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res. 2004;64(2):711-8. (Pubitemid 38120914)
40. Kim EJ, Shim G, Kim K, Kwon IC, Oh YK, Shim CK. Hyaluronic acid complexed to biodegradable poly L-arginine for targeted delivery of siRNAs. J Gene Med. 2009;11(9):791-803.
41. Yang X, Grailer JJ, Rowland IJ, Javadi A, Hurley SA, Matson VZ, et al. Multifunctional stable and pH-responsive polymer vesicles formed by heterofunctional triblock copolymer for targeted anticancer drug delivery and ultrasensitive MR Imaging. ACS Nano. 2010;4(11):6805-17.
42. Godden D, Brennan PA, Milne J. Update on melanoma: the present position. Br J Oral Maxillofac Surg. 2010;48(8):575-8.